BEAM

SEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 12

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2036-01-31

F7 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-26-033601 · ownership.xml · derivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0001193125-26-033598 · ownership.xml · derivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,500

Underlying: Common Stock · 88,500 shares

Expires 2036-01-31

F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date.

SEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 11

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,672

Underlying: Common Stock · 25,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 989,573

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $27.87 to $28.82 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 10

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,672

Underlying: Common Stock · 5,664 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F6 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a certain development milestone related to base editing applications. On April 3, 2024, the board of directors of BEAM determined that this performance condition was achieved, resulting in the vesting of 99,336 shares.

SEC source: 0001193125-26-033600 · ownership.xml · derivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,336 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022, and December 31, 2022.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $29.66 to $29.92 inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 995,334

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $28.65 to $29.64 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-033600 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,006,003

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-26-022563 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,813

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.00 to $35.015, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-022557 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,667

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

SEC source: 0001193125-26-017942 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,011

F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025.

SEC source: 0001193125-26-016552 · ownership.xml · nonDerivative · entry 3

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,038

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.38 to $35.485, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-016552 · ownership.xml · nonDerivative · entry 2

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 97,597

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.355 to $35.34, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-016552 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,556

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.17 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-26-002448 · ownership.xml · nonDerivative · entry 1

Emany Sravan Kumar · CIK 0001897662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,706

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2025.

SEC source: 0001193125-26-002427 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,667

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0001193125-26-002422 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,364

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0001193125-25-255853 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FMR Capital, Inc.

Disclosed balance after: 14

SEC source: 0001193125-25-234461 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 841,231

SEC source: 0001193125-25-230084 · ownership.xml · derivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,336

Underlying: Common Stock · 25,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022.

SEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.22 to $25.05, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

SEC source: 0001193125-25-230195 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,045

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021 and September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

SEC source: 0001193125-25-230148 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,921

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

SEC source: 0001193125-25-230084 · ownership.xml · derivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,336

Underlying: Common Stock · 25,000 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F5 · derivative.exercise_date: On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,396 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, June 30, 2022, and December 31, 2022.

SEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,667

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.14 to $24.92, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001193125-25-230084 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,011,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2025.

F2 · balance_after: Includes 418 shares acquired by the Reporting Person under the Beam Therapeutics Inc. ("BEAM") Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025.

SEC source: 0000950170-25-101143 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 2,073,665

SEC source: 0000950170-25-094002 · ownership.xml · nonDerivative · entry 2

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,864

F3 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.

SEC source: 0000950170-25-094002 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,740

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · balance_after: Includes 372 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.

SEC source: 0000950170-25-083053 · ownership.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083056 · ownership.xml · derivative · entry 1

Walsh Kathleen E · CIK 0001667866 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083054 · ownership.xml · derivative · entry 1

Shaw Christi · CIK 0001702473 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2025-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083055 · ownership.xml · derivative · entry 1

Fishman Mark · CIK 0001786003 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083051 · ownership.xml · derivative · entry 1

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083050 · ownership.xml · derivative · entry 1

COOPER GRAHAM K · CIK 0001396943 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2035-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-083052 · ownership.xml · derivative · entry 1

Guindo Chirfi · CIK 0001722753 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,662

Underlying: Common Stock · 33,662 shares

Expires 2025-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000950170-25-050852 · ownership.xml · nonDerivative · entry 2

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,742

F3 · kind: The shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.20 to $18.12, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission , upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-050855 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,512

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-050857 · ownership.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 986,249

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: Includes 753 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2025.

SEC source: 0000950170-25-050859 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,294

F1 · kind: shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-050856 · ownership.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,216

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-050852 · ownership.xml · nonDerivative · entry 1

Simon Amy · CIK 0001963879 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,739

F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-049761 · ownership.xml · nonDerivative · entry 1

Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,527

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

SEC source: 0000950170-25-049769 · ownership.xml · nonDerivative · entry 1

Bellon Christine · CIK 0001963878 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,968

F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.